You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,066,985


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,066,985
Title:Reovirus for the treatment of cellular proliferative disorders
Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.
Inventor(s): Lee; Patrick W. K. (Halifax, CA), Strong; James (Calgary, CA), Coffey; Matthew C. (Calgary, CA)
Assignee: Oncolytics Biotech Inc. (Calgary, Alberta, CA)
Application Number:12/323,223
Patent Claims:1. A method of treating a ras-mediated neoplasm in a human, comprising: (a) administering to the human an effective amount of a reovirus to result in substantial oncolysis of the cells of the ras-mediated neoplasm; and (b) administering to the human an effective amount of a chemotherapeutic agent.

2. The method of claim 1, wherein step (a) is performed prior to step (b).

3. The method of claim 1, wherein step (b) is performed prior to step (a).

4. The method of claim 1, wherein the reovirus is a mammalian reovirus.

5. The method of claim 4, wherein the mammalian reovirus is a human reovirus.

6. The method of claim 1, wherein the reovirus is selected from the group consisting of serotype 1 reovirus, serotype 2 reovirus and serotype 3 reovirus.

7. The method of claim 1, wherein more than one dose of reovirus is administered.

8. The method of 1, wherein the reovirus is administered by injection into or near the ras-mediated neoplasm.

9. The method of claim 1, wherein the effective amount of the reovirus is from about 10.sup.2 pfu/kg body weight to about 10.sup.13 pfu/kg body weight.

10. The method of claim 1, wherein the chemotherapeutic agent is selected from the group consisting of 5-fluorouracil, mitomycin C, methotrexate, hydroxyurea, cyclophosphamide, dacarbazine, mitoxantrone, epirubicin, doxorubicin, herceptin, etoposide, pregnasome, carboplatin, cisplatin, taxol, taxotere, tamoxifen, anti-estrogens, interferons, aromatase inhibitors, progestational agents and LHRH analogs.

11. The method of claim 1, wherein the chemotherapeutic agent is taxol.

12. The method of claim 1, wherein the chemotherapeutic agent is cisplatin.

13. The method of claim 1, wherein the chemotherapeutic agent is cyclophosphamide.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.